Bone Biologics Corp
Close on Oct 19, 2026
- Market cap
- $737.57K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Bone Biologics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Bone Biologics filed with the SEC
Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics Announces Pricing of $5.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biologics Announces Closing of $5.0 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Other events · EX-99.1 to Form 8-K
Biologics Announces 1-for-6 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
Regulation FD disclosure · EX-99.1 to Form 8-K
Biologics Announces Pricing of $2.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biologics Announces Closing of $2.0 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Reports Progress with NB1 Clinical Program
Other events · EX-99.1 to Form 8-K
Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Other events · EX-99.1 to Form 8-K
Biologics Announces 1-for-8 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biologics Prices $5.0 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biologics CEO Issues Letter to Stockholders
Other events · EX-99.1 to Form 8-K
Biologics Announces Closing of $5,100,000 Underwritten Public Offering
Other events · EX-99.1 to Form 8-K
Biologics Prices $5,100,000 Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq
Other events · EX-99.1 to Form 8-K
Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K